The Technical Analyst
Inflarx NV [IFRX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Inflarx NV Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.21% €1.390
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 81.85 mill |
| EPS: | -0.830 |
| P/E: | -1.670 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 58.88 mill |
| Avg Daily Volume: | 0.228 mill |
| RATING 2024-04-25 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.670 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.28x |
| Company: PE -1.670 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
€0.233 (-83.24%) €-1.157 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
€ 1.263 - 1.517 ( +/- 9.14%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - €1.390
Forecast 2: 16:00 - €1.390
Forecast 3: 16:00 - €1.390
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €1.390 (2.21% ) |
| Volume | 0.146 mill |
| Avg. Vol. | 0.228 mill |
| % of Avg. Vol | 64.13 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IFRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IFRX
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Latest Press Releases
2024-04-24 07:30:00 - Press Release
Inflarx To Participate In Capital One Securities 1st Annual Biotech/biopharma Disrupters Event
Jena, germany, april 24, 2024 (globe newswire) -- inflarx n.v. (nasdaq: ifrx), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the company will participate in the capital one securities 1st annual biotech/biopharma disrupters event to be held in new york city.
2024-03-21 07:00:00 - Press Release
Inflarx Reports Full Year 2023 Results And Announces Inf904 Development Plans
Jena, germany, march 21, 2024 (globe newswire) -- inflarx n.v. (nasdaq: ifrx), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial and operating results for the year ended december 31, 2023, and provided a comprehensive strategic update on its future development and operational plans.
2024-03-19 07:30:00 - Press Release
Inflarx To Announce Development Plans For Inf904 And 2023 Financial Results On March 21, 2024
Jena, germany, march 19, 2024 (globe newswire) -- inflarx n.v. (nasdaq: ifrx), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a conference call this thursday, march 21, 2024 at 8:00 am et / 1:00 pm cet to discuss the company's anticipated development plans for inf904, inflarx's orally available c5ar inhibitor with best-in-class potential. the company will also publish its financial and operating results for the fourth quarter and full year 2023 on march 21, 2024, in advance of the call.
2024-02-22 07:30:00 - Press Release
Inflarx Appoints Jan Medina As Head Of Investor Relations
Jena, germany, feb. 22, 2024 (globe newswire) -- inflarx n.v. (nasdaq: ifrx), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of jan medina, cfa, as vice president and head of investor relations of inflarx. mr. medina brings over 25 years of extensive experience across the life sciences sector and capital markets, including in the areas of investor relations, communications and equity research.
2024-01-25 07:30:00 - Press Release
Inflarx Announces Initiation Of Its Commitment Program For Gohibic®(vilobelimab) To Help Broaden Access For Eligible Patients
Ann arbor, mich., jan. 25, 2024 (globe newswire) -- inflarx pharmaceuticals inc., a subsidiary of inflarx n.v. (nasdaq: ifrx), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that the company has launched the inflarx commitment program (commitment program). pursuant to the commitment program, the cost of gohibic (vilobelimab) will be refunded for up to six (6) administered inpatient doses (the full treatment course) to institutions that meet the eligibility requirements*, for patients who were administered gohibic in line with its eua and who died due to covid-19 in the intensive care unit.
Latest News
2024-03-21 09:46:05 - Zacks Investment Research
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
InflaRx N.V. (IFRX) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.20.
2024-03-19 07:30:00 - GlobeNewsWire
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to discuss the Company's anticipated development plans for INF904, InflaRx's orally available C5aR inhibitor with best-in-class potential. The Company will also publish its financial and operating results for the fourth quarter and full year 2023 on March 21, 2024, in advance of the call.
2023-12-01 11:18:54 - Zacks Investment Research
Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishing
InflaRx N.V. (IFRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately.
2023-11-28 11:17:49 - Zacks Investment Research
After Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)
InflaRx N.V. (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
2023-11-06 11:19:14 - Zacks Investment Research
InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
InflaRx N.V. (IFRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
2023-09-06 17:31:58 - Seeking Alpha
InflaRx: Small German Company Targeting A Rare Indication
InflaRx is a developer of complement mediated therapies for inflammatory diseases. Their lead asset, vilobelimab, is a C5a inhibitor targeting Pyoderma Gangraenosum in a phase 3 trial. The company has a cash runway of 7-8 quarters and raised $40mn in a public offering in April.
2023-09-01 15:47:11 - Zacks Investment Research
InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why
Shares of InflaRx (IFRX) show an upward trajectory after it obtained authorization for its first-ever marketed drug, which is approved for the treatment of critically ill COVID-19 patients.
2023-04-07 10:21:36 - The Motley Fool
Why InflaRx Stock Skyrocketed This Week
InflaRx stock has soared on news that the company's Gohibic drug had received Emergency Use Authorization from the FDA. Analysts expect that Gohibic will be priced above $20,000 per treatment course.
2023-04-05 15:51:05 - Proactive Investors
InflaRx shares pop on FDA emergency use authorization of Covid-19 treatment injection
The US Food and Drug Administration (FDA) granted emergency-use authorization (EUA) to InflaRx NV's monoclonal antibody for the treatment of hospitalized Covid-19 patients, sending the company's stock soaring. Shares of the German biopharmaceutical company skyrocketed nearly 60% to $6.02 on Wednesday.
2023-04-05 12:12:10 - Zacks Investment Research
InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment
InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.